Stock traders buy large volume of put options from Evelo Biosciences (NASDAQ:EVLO)

Evelo Biosciences, Inc. (NASDAQ:EVLO – Get Rating) saw some unusual options trading on Wednesday. Equity investors bought 1,885 put options on the stock. This is a 1,101% increase from the average volume of 157 put options.

In other news from Evelo Biosciences, major shareholder Ventures Fund Iv Gene Flagship acquired 27,397,259 shares of the company in a transaction on Friday, May 27. The shares were purchased at an average cost of $1.46 per share, with a total value of $39,999,998.14. Following the completion of the acquisition, the insider now owns 13,698,630 shares of the company, valued at $19,999,999.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC’s website. 6.10% of the shares are currently held by insiders of the company.

Hedge funds and other institutional investors have recently increased or reduced their stakes in the company. The New York State Common Retirement Fund raised its position in shares of Evelo Biosciences by 57.8% in the fourth quarter. The New York State Common Retirement Fund now owns 15,765 shares of the company valued at $96,000 after acquiring 5,777 additional shares in the last quarter. AE Wealth Management LLC increased its position in Evelo Biosciences by 21.5% during the fourth quarter. AE Wealth Management LLC now owns 19,528 shares of the company worth $119,000 after buying 3,451 additional shares in the last quarter. Belvedere Trading LLC increased its position in Evelo Biosciences by 75.1% during the fourth quarter. Belvedere Trading LLC now owns 241,137 shares of the company worth $1,182,000 after purchasing an additional 103,386 shares last quarter. Walleye Capital LLC bought a new position in Evelo Biosciences during the first quarter worth approximately $38,000. Finally, Group One Trading LP increased its position in Evelo Biosciences by 93.4% during the first quarter. Group One Trading LP now owns 452,939 shares of the company worth $1,535,000 after purchasing an additional 218,730 shares last quarter. Institutional investors and hedge funds own 92.20% of the company’s shares.

(A d)

What is the most productive stock you have ever owned? Dividends from these stocks have grown so rapidly over the years that they now earn us an average of 26%!

When you start getting paid 26% on your money, your financial troubles tend to evaporate.

Shares of EVLO opened at $2.09 on Thursday. The company has a current ratio of 2.67, a quick ratio of 2.67 and a debt ratio of 5.37. Evelo Biosciences has a 12 month minimum of $1.42 and a 12 month maximum of $13.08. The stock’s 50-day moving average is $2.10 and its two-hundred-day moving average is $3.29. The company has a market capitalization of $112.15 million, a P/E ratio of -0.90 and a beta of 1.64.

Evelo Biosciences (NASDAQ:EVLO – Get Rating) last reported results on Thursday, May 12. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.02. Equity research analysts expect Evelo Biosciences to post EPS of -2.01 for the current year.

About Evelo Biosciences (Get an assessment)

Evelo Biosciences, Inc, a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in a Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as the hyperinflammatory response associated with COVID-19.

Featured articles

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Evelo Biosciences right now?

Before you consider Evelo Biosciences, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Evelo Biosciences wasn’t on the list.

While Evelo Biosciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Comments are closed.